PL2882715T3 - Pochodne pirazolowe i ich zastosowanie jako antagonistów LPAR5 - Google Patents
Pochodne pirazolowe i ich zastosowanie jako antagonistów LPAR5Info
- Publication number
- PL2882715T3 PL2882715T3 PL13723151T PL13723151T PL2882715T3 PL 2882715 T3 PL2882715 T3 PL 2882715T3 PL 13723151 T PL13723151 T PL 13723151T PL 13723151 T PL13723151 T PL 13723151T PL 2882715 T3 PL2882715 T3 PL 2882715T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrazole derivatives
- lpar5 antagonists
- lpar5
- antagonists
- pyrazole
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 150000003217 pyrazoles Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305552 | 2012-05-18 | ||
| EP13723151.0A EP2882715B1 (en) | 2012-05-18 | 2013-05-16 | Pyrazole derivatives and their use as lpar5 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2882715T3 true PL2882715T3 (pl) | 2017-04-28 |
Family
ID=48446368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13723151T PL2882715T3 (pl) | 2012-05-18 | 2013-05-16 | Pochodne pirazolowe i ich zastosowanie jako antagonistów LPAR5 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9346762B2 (pl) |
| EP (1) | EP2882715B1 (pl) |
| JP (1) | JP6257596B2 (pl) |
| KR (1) | KR20150010973A (pl) |
| CN (1) | CN104302625B (pl) |
| AU (1) | AU2013261718B2 (pl) |
| BR (1) | BR112014028406A2 (pl) |
| CA (1) | CA2871542A1 (pl) |
| CY (1) | CY1118618T1 (pl) |
| DK (1) | DK2882715T3 (pl) |
| ES (1) | ES2612205T3 (pl) |
| HR (1) | HRP20170098T1 (pl) |
| HU (1) | HUE032890T2 (pl) |
| IL (1) | IL235221A (pl) |
| LT (1) | LT2882715T (pl) |
| MX (1) | MX347615B (pl) |
| PL (1) | PL2882715T3 (pl) |
| PT (1) | PT2882715T (pl) |
| RU (1) | RU2645344C2 (pl) |
| SG (1) | SG11201407210SA (pl) |
| SI (1) | SI2882715T1 (pl) |
| WO (1) | WO2013171317A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2015521183A (ja) | 2012-05-18 | 2015-07-27 | サノフイ | ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用 |
| EP3942934A1 (en) * | 2015-06-12 | 2022-01-26 | Vettore, LLC | Mct4 inhibitors for treating disease |
| MX391489B (es) * | 2016-12-12 | 2025-03-21 | Vettore Llc | Inhibidores heterociclicos de mct4. |
| IL291783A (en) | 2019-10-02 | 2022-06-01 | Domain Therapeutics | ep4 prostaglandin e2 receptor antagonists |
| WO2024092205A1 (en) * | 2022-10-27 | 2024-05-02 | The Trustees Of Indiana University | Inhibition of ship1 as a therapeutic strategy for the treatment of alzheimer's disease |
| CN119930520B (zh) * | 2023-11-03 | 2026-03-06 | 中国药科大学 | N-芳基吡唑类化合物及其药物组合物和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1230441B (it) | 1989-02-07 | 1991-10-23 | Acraf | Eteri della serie dell'indazolo |
| US7279478B2 (en) | 2002-09-04 | 2007-10-09 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
| CA2677736A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of ppar-gamma |
| EP2238127B1 (en) | 2007-12-26 | 2012-08-15 | Sanofi | Pyrazole-carboxamide derivatives as p2y12 antagonists |
| EP2262778B8 (en) | 2008-03-07 | 2020-01-01 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| PL2254870T3 (pl) * | 2008-03-07 | 2016-07-29 | Acraf | Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1 |
| WO2010106290A1 (fr) * | 2009-03-19 | 2010-09-23 | Sanofi-Aventis | Derives d'indazole inhibiteurs d'hsp90, compositions les contenant et utilisation |
| PL2462119T3 (pl) * | 2009-08-03 | 2014-10-31 | Acraf | Sposób wytwarzania 1-benzylo-3-hydroksymetylo-1H-indazolu i jego pochodnych oraz potrzebnych magnezowych związków pośrednich |
| ES2530345T3 (es) | 2010-09-02 | 2015-03-02 | Merck Patent Gmbh | Derivados de pirazolopiridinona como antagonistas del receptor del LPA |
| JP2015521183A (ja) | 2012-05-18 | 2015-07-27 | サノフイ | ピリジン誘導体および病理学的血栓形成に関連する状態の治療へのその使用 |
-
2013
- 2013-05-16 EP EP13723151.0A patent/EP2882715B1/en not_active Not-in-force
- 2013-05-16 JP JP2015512072A patent/JP6257596B2/ja not_active Expired - Fee Related
- 2013-05-16 ES ES13723151.0T patent/ES2612205T3/es active Active
- 2013-05-16 SG SG11201407210SA patent/SG11201407210SA/en unknown
- 2013-05-16 HR HRP20170098TT patent/HRP20170098T1/hr unknown
- 2013-05-16 BR BR112014028406A patent/BR112014028406A2/pt not_active Application Discontinuation
- 2013-05-16 LT LTEP13723151.0T patent/LT2882715T/lt unknown
- 2013-05-16 US US14/401,050 patent/US9346762B2/en not_active Expired - Fee Related
- 2013-05-16 PL PL13723151T patent/PL2882715T3/pl unknown
- 2013-05-16 CA CA2871542A patent/CA2871542A1/en not_active Abandoned
- 2013-05-16 AU AU2013261718A patent/AU2013261718B2/en not_active Ceased
- 2013-05-16 SI SI201330499A patent/SI2882715T1/sl unknown
- 2013-05-16 WO PCT/EP2013/060171 patent/WO2013171317A1/en not_active Ceased
- 2013-05-16 KR KR20147033843A patent/KR20150010973A/ko not_active Ceased
- 2013-05-16 DK DK13723151.0T patent/DK2882715T3/en active
- 2013-05-16 MX MX2014014011A patent/MX347615B/es active IP Right Grant
- 2013-05-16 RU RU2014151360A patent/RU2645344C2/ru not_active IP Right Cessation
- 2013-05-16 HU HUE13723151A patent/HUE032890T2/hu unknown
- 2013-05-16 PT PT137231510T patent/PT2882715T/pt unknown
- 2013-05-16 CN CN201380025967.9A patent/CN104302625B/zh not_active Expired - Fee Related
-
2014
- 2014-10-20 IL IL235221A patent/IL235221A/en active IP Right Grant
-
2017
- 2017-02-08 CY CY20171100175T patent/CY1118618T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150010973A (ko) | 2015-01-29 |
| CA2871542A1 (en) | 2013-11-21 |
| JP2015517514A (ja) | 2015-06-22 |
| JP6257596B2 (ja) | 2018-01-10 |
| AU2013261718B2 (en) | 2017-10-19 |
| ES2612205T3 (es) | 2017-05-12 |
| AU2013261718A1 (en) | 2014-12-18 |
| CN104302625A (zh) | 2015-01-21 |
| CN104302625B (zh) | 2017-04-19 |
| RU2014151360A (ru) | 2016-07-10 |
| HUE032890T2 (hu) | 2017-11-28 |
| DK2882715T3 (en) | 2017-02-13 |
| SI2882715T1 (sl) | 2017-03-31 |
| PT2882715T (pt) | 2016-12-30 |
| BR112014028406A2 (pt) | 2017-06-27 |
| LT2882715T (lt) | 2017-02-10 |
| HRP20170098T1 (hr) | 2017-03-24 |
| US20150141477A1 (en) | 2015-05-21 |
| RU2645344C2 (ru) | 2018-02-21 |
| SG11201407210SA (en) | 2014-12-30 |
| MX347615B (es) | 2017-05-04 |
| CY1118618T1 (el) | 2017-07-12 |
| MX2014014011A (es) | 2015-02-12 |
| EP2882715B1 (en) | 2016-11-09 |
| WO2013171317A1 (en) | 2013-11-21 |
| EP2882715A1 (en) | 2015-06-17 |
| IL235221A (en) | 2016-06-30 |
| US9346762B2 (en) | 2016-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL234590A0 (en) | Modified pyrazole-containing compounds and their use as pesticides | |
| EP2828258A4 (en) | NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE | |
| IL234628A0 (en) | Imidazolyl-pyrimidines are converted into amino-indolyl and their use as drugs | |
| IL238238A0 (en) | Il-6 antagonists and their use | |
| SG11201506813QA (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| PL2848254T3 (pl) | Pochodne pirazolu i ich zastosowanie w celach medycznych | |
| ZA201405253B (en) | Heterocyclic compounds and methods for their use | |
| ZA201405257B (en) | Heterocyclic compounds and methods for their use | |
| ZA201405255B (en) | Heterocyclic compounds and methods for their use | |
| ZA201502144B (en) | N-prop-2-ynyl carboxamide derivatives and their use as trpa1 antagonists | |
| AP3611A (en) | Heterocyclic compounds and their uses | |
| ZA201405392B (en) | Substituted phenylimidazopyrazoles and use thereof | |
| LT2882715T (lt) | Pirazolo dariniai ir jų panaudojimas kaip lpar5 antagonistų | |
| IL233625A0 (en) | Enaminoketones containing cf3o and their use for the preparation of pyrazoles containing cf3o | |
| IL238461A0 (en) | 1 hindole-3-carboxamide derivatives and their use as p2y12 inhibitors | |
| GB201219289D0 (en) | Pyrazole derivatives | |
| GB201219296D0 (en) | Pyrazole derivatives | |
| GB201218245D0 (en) | Pyrazole derivatives |